Prior to joining BioAgilytix, he was Chief Financial Officer at Metabolon, the world leader in the field of metabolomics, where he helped successfully engineer the purchase of complimentary research technology company, Lipomics. He was also VP of Global Finance – Clinical Division at Inveresk Research, where he led due diligence and integration activities involved in several acquisition opportunities, and was responsible for financial oversight for the global clinical division related to the company’s IPO and sale to Charles River Laboratories. Prior to joining BioAgilytix, he was Chief Financial Officer at Metabolon, the world leader in the field of metabolomics, where he helped successfully engineer the purchase of complimentary research technology company, Lipomics. He was also VP of Global Finance – Clinical Division at Inveresk Research, where he led due diligence and integration activities involved in several acquisition opportunities, and was responsible for financial oversight for the global clinical division related to the company’s IPO and sale to Charles River Laboratories.

Biopharmaceutical Science, Business Management